Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Market Movers Investor Summit on Tuesday, May 5, 2026 at 9:00 AM ET at 48 Wall Street (the original Bank of New York). Christer Rosén, chairman and CEO, will deliver the company presentation.
The summit runs May 4–5, 2026, and features company presentations, fireside chats, one-on-one meetings, and networking for public and private company executives, fund managers, and family offices. Invitation requests available via the summit website.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq in New York City. Christer Rosén, chairman and CEO, will discuss recent performance and future growth plans and participate in investor meetings and panel sessions.
The conference hosts presenting companies, fireside chats, facilitated 1:1 investor meetings and sponsors from the capital markets ecosystem.
Jupiter Neurosciences (NASDAQ: JUNS) appointed Kristopher Fishman and Sanjiv Lal to the Nugevia™ Advisory Board, adding direct distribution expertise across compounding pharmacies and wellness channels. The company cites an addressable U.S. nutraceutical market of over $1.5 billion. Nugevia™ uses JOTROL™ micellar delivery and includes three formulations: PWR, MND, and GLO. The JOTROL platform supports Jupiter’s clinical pipeline, including a Phase IIa Parkinson’s trial that received FDA clearance. Products are currently direct-to-consumer at the company website, and Jupiter is expanding into practitioner-led channels to leverage clinical-grade bioavailability data.
Jupiter Neurosciences (NASDAQ: JUNS) will present at Emerging Growth Conference 91 on April 2, 2026 at 10:15 AM ET to discuss clinical and commercial progress for JOTROL.
The live, interactive webcast is available via the conference link and an archived webcast will be posted on EmergingGrowth.com and the Emerging Growth YouTube channel after the event.
Jupiter Neurosciences (NASDAQ: JUNS) will present at the BIO Investment and Growth Summit 2026 on March 2, 2026 at 2:30 PM ET in Miami Beach. Management will discuss an FDA-cleared IND and the company’s ongoing Phase IIa Parkinson’s program and commercial progress with Nugevia.
Jupiter cites IND clearance in November 2025, preclinical JOTROL bioavailability improvements, repeat purchase rates ~25%, and ~3% return rates as early commercial validation.
Jupiter Neurosciences (NASDAQ: JUNS) was invited as the sole company to present progress at a private investor dinner on February 25, 2026 at Mar-a-Lago in Palm Beach. Management will update attendees on Phase IIa Parkinson’s progress, the neuroinflammation pipeline, and commercial execution of Nugevia™.
The event is invitation-only for accredited investors, organized by the Money Channel NYC, and management said it intends to continue direct investor engagement; contact ir@jupiterneurosciences.com for meeting requests.
Jupiter Neurosciences (NASDAQ: JUNS) entered an Omnibus Amendment with YA II PN, Ltd. that defers installment repayments to April 1, 2026 while keeping the $6.0 million core economic financing terms unchanged. The amendment modifies timing and application mechanics only and adds no new pricing, resets, or commitments.
Management says the change aligns capital timing with advancing its Phase II Parkinson’s program and scaling commercial sales of Nugevia (JOTROL resveratrol), which shows ~25% repeat purchases and ~3% returns. The company remains in compliance with its transaction documents.
Jupiter Neurosciences (NASDAQ: JUNS) announced a strategic initiative on January 28, 2026 to expand its Nugevia™ consumer longevity line to support people using GLP-1 weight-loss therapies. The move aligns the company's clinical-stage JOTROL™ platform with a direct-to-consumer longevity business targeting mitochondrial, metabolic, and neuroinflammatory support.
Jupiter cited rising GLP-1 adoption and consumer concerns—including a reported 4,600% spike in searches for “Ozempic face” and reports that significant weight loss may make patients appear up to 5 years older—as rationale for positioning Nugevia™ MND and PWR as complementary products to address related biological stresses.
Jupiter Neurosciences (NASDAQ:JUNS) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.
Christer Rosén, Chairman and CEO, will deliver a company presentation and is available for one-on-one investor meetings. Investors can request an investor pass at no cost to attend. More information about the company is available at the company website.
Jupiter Neurosciences (NASDAQ: JUNS) invites investors to an exclusive live webinar on January 6, 2026 at 4:15 p.m. ET, hosted by RedChip Companies. Chairman and CEO Chister Rosén will review Jupiter's resveratrol-based platform JOTROL™, its differentiated bioavailability profile, and plans for an upcoming Phase 2a Parkinson’s disease trial.
The presentation will also cover Jupiter’s dual-path strategy: early commercialization of the Nugevia™ longevity product line and the pharmaceutical development pathway, plus how recent financing supports execution. A live Q&A follows. Registration is free at the RedChip webinar page and questions can be pre-submitted to JUNS@redchip.com.